The final round of AI Madness 2026 is here. We pitted ChatGPT against Claude in 7 brutal, real-world benchmarks — from senior ...
Summit Therapeutics has revealed that a second pivotal trial of its Akeso-partnered PD-1xVEGF bispecific ivonescimab has failed to show an improvement in overall survival in a lung cancer trial. New ...
MPCBMountain Pacific Bancorp, Inc. PVNOProVision Operation Systems, Inc. NZIHNZJ Holdings Inc. LGYVLegacy Ventures International, Inc. GRUIGrupo Resilient ...
School leaders Cady Ching and Dan Effland join Class Disrupted to discuss visions of ‘Summit 3.0.’ ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results